Pfizer’s Chantix Has Short-Term Edge, But GSK Touts OTC Patch For Long Term
This article was originally published in The Tan Sheet
Executive Summary
People using Pfizer's smoking cessation Rx drug Chantix are more likely to abstain and experience fewer withdrawal symptoms at the end of treatment than smokers who use the nicotine replacement therapy provided in GlaxoSmithKline's OTC NicoDerm CQ Clean Patch, a Pfizer-funded study shows
You may also be interested in...
GSK Lights Fire Under Educating Consumers On Smoking Cessation OTCs
GlaxoSmithKline says it is stepping up public relations efforts to tell consumers that its OTC smoking cessation products are not linked to problems reported with Pfizer's Rx drug Chantix
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.